| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 1 | 111 | 2026 | 824 | 23.480 |
Why?
|
| Autoantibodies | 38 | 2026 | 423 | 5.920 |
Why?
|
| Diabetes Mellitus, Type 2 | 25 | 2026 | 1357 | 5.850 |
Why?
|
| C-Peptide | 22 | 2025 | 93 | 4.420 |
Why?
|
| Islets of Langerhans | 17 | 2021 | 146 | 4.400 |
Why?
|
| Insulin | 27 | 2026 | 1128 | 3.190 |
Why?
|
| Insulin Resistance | 9 | 2024 | 665 | 3.070 |
Why?
|
| Hypoglycemic Agents | 13 | 2026 | 456 | 2.430 |
Why?
|
| Diabetic Ketoacidosis | 12 | 2024 | 163 | 2.290 |
Why?
|
| Polymorphism, Single Nucleotide | 13 | 2026 | 2746 | 2.050 |
Why?
|
| Blood Glucose | 20 | 2024 | 1082 | 2.040 |
Why?
|
| Autoimmunity | 13 | 2020 | 172 | 1.920 |
Why?
|
| Adolescent | 69 | 2026 | 20151 | 1.860 |
Why?
|
| Transcription Factor 7-Like 2 Protein | 6 | 2022 | 25 | 1.780 |
Why?
|
| Genetic Predisposition to Disease | 21 | 2026 | 3263 | 1.740 |
Why?
|
| Child | 74 | 2026 | 25299 | 1.660 |
Why?
|
| Glucose Tolerance Test | 10 | 2025 | 199 | 1.330 |
Why?
|
| Humans | 134 | 2026 | 127335 | 1.310 |
Why?
|
| Insulin-Secreting Cells | 6 | 2024 | 132 | 1.280 |
Why?
|
| Child, Preschool | 44 | 2026 | 14463 | 1.210 |
Why?
|
| Genetic Heterogeneity | 3 | 2018 | 129 | 1.070 |
Why?
|
| Glutamate Decarboxylase | 6 | 2017 | 42 | 1.070 |
Why?
|
| Male | 78 | 2026 | 62795 | 1.060 |
Why?
|
| Disease Progression | 20 | 2026 | 2120 | 1.050 |
Why?
|
| Female | 79 | 2026 | 68638 | 1.030 |
Why?
|
| Young Adult | 27 | 2026 | 9698 | 0.960 |
Why?
|
| Hypoglycemia | 6 | 2018 | 176 | 0.880 |
Why?
|
| Pediatric Obesity | 6 | 2026 | 409 | 0.870 |
Why?
|
| Body Mass Index | 10 | 2023 | 1659 | 0.860 |
Why?
|
| Obesity | 11 | 2026 | 2337 | 0.830 |
Why?
|
| Adult | 41 | 2026 | 30544 | 0.820 |
Why?
|
| Risk Factors | 24 | 2026 | 10612 | 0.820 |
Why?
|
| Immunoglobulin A | 2 | 2024 | 205 | 0.810 |
Why?
|
| Leptin | 2 | 2023 | 218 | 0.780 |
Why?
|
| HLA-DQ Antigens | 6 | 2018 | 19 | 0.770 |
Why?
|
| Puberty | 2 | 2021 | 103 | 0.760 |
Why?
|
| Minority Groups | 3 | 2020 | 256 | 0.740 |
Why?
|
| Prediabetic State | 4 | 2026 | 65 | 0.720 |
Why?
|
| Metformin | 1 | 2023 | 159 | 0.710 |
Why?
|
| Infant | 23 | 2024 | 12808 | 0.700 |
Why?
|
| Biomarkers | 8 | 2024 | 3235 | 0.690 |
Why?
|
| Genetic Linkage | 2 | 2021 | 463 | 0.690 |
Why?
|
| Hyperglycemia | 4 | 2020 | 225 | 0.680 |
Why?
|
| Diabetes, Gestational | 1 | 2022 | 107 | 0.670 |
Why?
|
| Diagnostic Errors | 1 | 2024 | 330 | 0.650 |
Why?
|
| Disease Susceptibility | 1 | 2021 | 278 | 0.650 |
Why?
|
| Overweight | 7 | 2020 | 372 | 0.570 |
Why?
|
| Diabetes Mellitus | 4 | 2026 | 873 | 0.560 |
Why?
|
| Cohort Studies | 16 | 2020 | 4978 | 0.560 |
Why?
|
| Flatfishes | 3 | 2006 | 3 | 0.560 |
Why?
|
| Age of Onset | 6 | 2020 | 611 | 0.550 |
Why?
|
| Fish Diseases | 3 | 2006 | 7 | 0.550 |
Why?
|
| Phenotype | 9 | 2024 | 4308 | 0.550 |
Why?
|
| Decision Support Techniques | 1 | 2021 | 291 | 0.550 |
Why?
|
| Adiposity | 2 | 2020 | 205 | 0.540 |
Why?
|
| Age Factors | 12 | 2024 | 2803 | 0.530 |
Why?
|
| Cross-Sectional Studies | 7 | 2025 | 3683 | 0.530 |
Why?
|
| Prospective Studies | 14 | 2024 | 6241 | 0.520 |
Why?
|
| Diabetes Complications | 1 | 2018 | 194 | 0.510 |
Why?
|
| Osteocalcin | 1 | 2017 | 45 | 0.510 |
Why?
|
| Protozoan Infections, Animal | 2 | 2006 | 4 | 0.500 |
Why?
|
| Twins, Monozygotic | 3 | 2008 | 124 | 0.480 |
Why?
|
| Hospitalization | 1 | 2024 | 1880 | 0.470 |
Why?
|
| Diseases in Twins | 2 | 2008 | 89 | 0.450 |
Why?
|
| Prognosis | 6 | 2024 | 4800 | 0.450 |
Why?
|
| Thinness | 1 | 2014 | 69 | 0.420 |
Why?
|
| Insulin Infusion Systems | 4 | 2023 | 64 | 0.420 |
Why?
|
| Genotype | 7 | 2026 | 2598 | 0.380 |
Why?
|
| Middle Aged | 20 | 2026 | 27818 | 0.380 |
Why?
|
| Retrospective Studies | 11 | 2026 | 17068 | 0.370 |
Why?
|
| Health Personnel | 1 | 2017 | 535 | 0.370 |
Why?
|
| Family | 4 | 2025 | 580 | 0.360 |
Why?
|
| Socioeconomic Factors | 6 | 2019 | 881 | 0.360 |
Why?
|
| Attitude of Health Personnel | 1 | 2017 | 695 | 0.350 |
Why?
|
| Blood Glucose Self-Monitoring | 4 | 2023 | 127 | 0.350 |
Why?
|
| HLA Antigens | 4 | 2026 | 218 | 0.330 |
Why?
|
| Sex Factors | 5 | 2024 | 1314 | 0.330 |
Why?
|
| Follow-Up Studies | 8 | 2024 | 5150 | 0.320 |
Why?
|
| Patient Preference | 1 | 2011 | 140 | 0.320 |
Why?
|
| Eukaryota | 2 | 2006 | 15 | 0.310 |
Why?
|
| Prevalence | 6 | 2024 | 2614 | 0.300 |
Why?
|
| Mass Screening | 3 | 2025 | 803 | 0.300 |
Why?
|
| Antibody Specificity | 3 | 2018 | 199 | 0.300 |
Why?
|
| Zinc Transporter 8 | 3 | 2017 | 5 | 0.280 |
Why?
|
| Hepatocyte Nuclear Factor 1-alpha | 2 | 2026 | 22 | 0.280 |
Why?
|
| Receptor-Like Protein Tyrosine Phosphatases, Class 8 | 5 | 2017 | 10 | 0.280 |
Why?
|
| Twins, Dizygotic | 2 | 2004 | 44 | 0.260 |
Why?
|
| Social Class | 2 | 2020 | 206 | 0.260 |
Why?
|
| Health Services Accessibility | 3 | 2020 | 661 | 0.260 |
Why?
|
| Genetic Testing | 3 | 2024 | 1056 | 0.260 |
Why?
|
| Administration, Oral | 2 | 2026 | 685 | 0.250 |
Why?
|
| Glucose | 4 | 2023 | 839 | 0.250 |
Why?
|
| Intestinal Diseases, Parasitic | 1 | 2006 | 41 | 0.240 |
Why?
|
| Dyslipidemias | 2 | 2021 | 235 | 0.240 |
Why?
|
| Major Histocompatibility Complex | 4 | 2017 | 54 | 0.240 |
Why?
|
| Cluster Analysis | 2 | 2024 | 410 | 0.240 |
Why?
|
| Cardiovascular Diseases | 2 | 2015 | 2036 | 0.230 |
Why?
|
| Health Status Disparities | 2 | 2020 | 268 | 0.230 |
Why?
|
| Haplotypes | 6 | 2026 | 525 | 0.220 |
Why?
|
| Social Determinants of Health | 2 | 2023 | 152 | 0.210 |
Why?
|
| Health Education | 1 | 2026 | 224 | 0.210 |
Why?
|
| Weight Gain | 3 | 2017 | 377 | 0.210 |
Why?
|
| Cytokines | 3 | 2024 | 1325 | 0.210 |
Why?
|
| Immunotherapy | 2 | 2024 | 742 | 0.210 |
Why?
|
| Glucagon-Like Peptide 1 | 2 | 2022 | 74 | 0.210 |
Why?
|
| Siblings | 1 | 2004 | 202 | 0.200 |
Why?
|
| Precision Medicine | 2 | 2024 | 346 | 0.200 |
Why?
|
| Genetic Vectors | 2 | 2017 | 891 | 0.200 |
Why?
|
| Alleles | 4 | 2017 | 1609 | 0.200 |
Why?
|
| Immunity, Innate | 1 | 2006 | 395 | 0.200 |
Why?
|
| HLA-DRB1 Chains | 3 | 2017 | 45 | 0.200 |
Why?
|
| United States | 10 | 2025 | 11386 | 0.190 |
Why?
|
| Immune System | 2 | 2020 | 93 | 0.190 |
Why?
|
| HLA-DR Antigens | 2 | 2005 | 69 | 0.180 |
Why?
|
| Self-Management | 2 | 2020 | 111 | 0.180 |
Why?
|
| Celiac Disease | 2 | 2017 | 75 | 0.180 |
Why?
|
| Sex Characteristics | 2 | 2020 | 314 | 0.180 |
Why?
|
| Genetic Association Studies | 1 | 2025 | 808 | 0.170 |
Why?
|
| Latent Autoimmune Diabetes in Adults | 1 | 2020 | 2 | 0.170 |
Why?
|
| Interleukin-4 | 2 | 2005 | 144 | 0.170 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 1 | 2020 | 46 | 0.160 |
Why?
|
| Colorectal Neoplasms | 2 | 2018 | 623 | 0.160 |
Why?
|
| Early Diagnosis | 1 | 2021 | 187 | 0.160 |
Why?
|
| HLA-DR2 Antigen | 1 | 1999 | 6 | 0.160 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2024 | 542 | 0.160 |
Why?
|
| Antibodies, Heterophile | 1 | 1999 | 8 | 0.160 |
Why?
|
| HLA-DQ alpha-Chains | 4 | 2017 | 17 | 0.160 |
Why?
|
| Genes, MHC Class II | 1 | 1999 | 33 | 0.160 |
Why?
|
| Biological Variation, Population | 1 | 2019 | 28 | 0.160 |
Why?
|
| Gene-Environment Interaction | 1 | 2020 | 126 | 0.160 |
Why?
|
| Autoimmune Diseases | 1 | 2002 | 270 | 0.160 |
Why?
|
| Chromosome Mapping | 1 | 2002 | 1054 | 0.150 |
Why?
|
| Healthcare Disparities | 2 | 2016 | 490 | 0.150 |
Why?
|
| Models, Immunological | 2 | 2015 | 37 | 0.150 |
Why?
|
| Global Health | 1 | 2024 | 609 | 0.150 |
Why?
|
| Prescription Drugs | 1 | 2020 | 51 | 0.150 |
Why?
|
| Cation Transport Proteins | 2 | 2017 | 99 | 0.150 |
Why?
|
| Adjuvants, Pharmaceutic | 1 | 2018 | 13 | 0.150 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2020 | 174 | 0.140 |
Why?
|
| Rectal Neoplasms | 1 | 2019 | 76 | 0.140 |
Why?
|
| Genetic Variation | 1 | 2024 | 1508 | 0.130 |
Why?
|
| Longitudinal Studies | 4 | 2019 | 1433 | 0.130 |
Why?
|
| Predictive Value of Tests | 3 | 2021 | 2234 | 0.130 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2020 | 259 | 0.130 |
Why?
|
| Fellowships and Scholarships | 1 | 2020 | 315 | 0.130 |
Why?
|
| Leg | 1 | 1997 | 126 | 0.130 |
Why?
|
| Pandemics | 1 | 2024 | 1140 | 0.130 |
Why?
|
| Gene Frequency | 1 | 2018 | 738 | 0.130 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2016 | 57 | 0.130 |
Why?
|
| Communication | 2 | 2019 | 512 | 0.130 |
Why?
|
| Colonic Neoplasms | 1 | 2019 | 258 | 0.120 |
Why?
|
| Cultural Characteristics | 1 | 2016 | 44 | 0.120 |
Why?
|
| Retroviridae | 1 | 2016 | 182 | 0.120 |
Why?
|
| Histocompatibility Testing | 3 | 2001 | 105 | 0.120 |
Why?
|
| Glucagon | 1 | 2016 | 146 | 0.120 |
Why?
|
| Exercise | 1 | 2022 | 845 | 0.120 |
Why?
|
| Acculturation | 1 | 2016 | 61 | 0.120 |
Why?
|
| Time Factors | 5 | 2016 | 6163 | 0.120 |
Why?
|
| Nutritional Sciences | 1 | 2016 | 65 | 0.120 |
Why?
|
| Perception | 1 | 2017 | 228 | 0.120 |
Why?
|
| Gastrointestinal Agents | 1 | 2016 | 61 | 0.120 |
Why?
|
| Health Literacy | 1 | 2016 | 74 | 0.120 |
Why?
|
| Cloning, Molecular | 1 | 2016 | 784 | 0.110 |
Why?
|
| Child Development | 1 | 2017 | 266 | 0.110 |
Why?
|
| Diabetic Foot | 1 | 1997 | 165 | 0.110 |
Why?
|
| Gene Transfer Techniques | 1 | 2016 | 336 | 0.110 |
Why?
|
| Stem Cell Transplantation | 1 | 2016 | 231 | 0.110 |
Why?
|
| Spain | 3 | 2006 | 60 | 0.110 |
Why?
|
| Registries | 3 | 2017 | 1539 | 0.110 |
Why?
|
| Language | 1 | 2016 | 205 | 0.110 |
Why?
|
| Calcium, Dietary | 1 | 2014 | 35 | 0.110 |
Why?
|
| Epitopes | 1 | 2016 | 420 | 0.110 |
Why?
|
| Dairy Products | 1 | 2014 | 43 | 0.110 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2017 | 458 | 0.110 |
Why?
|
| Seasons | 2 | 2006 | 318 | 0.110 |
Why?
|
| Adipokines | 1 | 2014 | 118 | 0.100 |
Why?
|
| Emigrants and Immigrants | 1 | 2016 | 165 | 0.100 |
Why?
|
| Polymorphism, Genetic | 4 | 2015 | 786 | 0.100 |
Why?
|
| Nuclear Family | 1 | 2013 | 49 | 0.100 |
Why?
|
| Qualitative Research | 1 | 2017 | 659 | 0.100 |
Why?
|
| Inflammation | 1 | 2020 | 1433 | 0.100 |
Why?
|
| Infant, Newborn | 5 | 2020 | 8366 | 0.100 |
Why?
|
| Poverty | 1 | 2016 | 447 | 0.090 |
Why?
|
| Insulin Antibodies | 3 | 2017 | 6 | 0.090 |
Why?
|
| Pancreas, Artificial | 1 | 2011 | 2 | 0.090 |
Why?
|
| Stem Cells | 1 | 2016 | 682 | 0.090 |
Why?
|
| Self Administration | 1 | 2011 | 46 | 0.090 |
Why?
|
| Twin Studies as Topic | 2 | 2001 | 13 | 0.090 |
Why?
|
| Alcohol Drinking | 1 | 2013 | 338 | 0.090 |
Why?
|
| Random Allocation | 2 | 2016 | 419 | 0.090 |
Why?
|
| Quality of Life | 1 | 2021 | 2029 | 0.080 |
Why?
|
| Area Under Curve | 2 | 2024 | 302 | 0.080 |
Why?
|
| Aging | 1 | 2017 | 1198 | 0.080 |
Why?
|
| Animals | 10 | 2017 | 33197 | 0.080 |
Why?
|
| Aquaculture | 2 | 2006 | 7 | 0.080 |
Why?
|
| Pregnancy | 1 | 2022 | 7402 | 0.080 |
Why?
|
| Risk Assessment | 3 | 2025 | 3589 | 0.080 |
Why?
|
| HLA-DQ beta-Chains | 2 | 2017 | 16 | 0.080 |
Why?
|
| Autoantigens | 2 | 2001 | 104 | 0.070 |
Why?
|
| Proportional Hazards Models | 3 | 2013 | 1369 | 0.070 |
Why?
|
| Mental Disorders | 1 | 2016 | 862 | 0.070 |
Why?
|
| Antigen-Presenting Cells | 2 | 2015 | 133 | 0.070 |
Why?
|
| T-Lymphocytes | 1 | 2016 | 1711 | 0.070 |
Why?
|
| Body Weight | 2 | 2015 | 971 | 0.070 |
Why?
|
| Survival Analysis | 2 | 2014 | 1498 | 0.070 |
Why?
|
| Spleen | 2 | 2006 | 253 | 0.070 |
Why?
|
| Treatment Outcome | 3 | 2024 | 12572 | 0.070 |
Why?
|
| Multivariate Analysis | 3 | 2017 | 1387 | 0.060 |
Why?
|
| Hypertension | 1 | 2015 | 1302 | 0.060 |
Why?
|
| Depression | 1 | 2015 | 1294 | 0.060 |
Why?
|
| Aged | 7 | 2019 | 20433 | 0.060 |
Why?
|
| Immunity, Active | 1 | 2006 | 6 | 0.060 |
Why?
|
| alpha-Macroglobulins | 1 | 2006 | 5 | 0.060 |
Why?
|
| Life Tables | 1 | 2006 | 25 | 0.060 |
Why?
|
| Complement Pathway, Alternative | 1 | 2006 | 14 | 0.060 |
Why?
|
| Muramidase | 1 | 2006 | 89 | 0.060 |
Why?
|
| Blood Cells | 1 | 2006 | 55 | 0.060 |
Why?
|
| Granulocytes | 1 | 2006 | 68 | 0.060 |
Why?
|
| Hepatocyte Nuclear Factor 4 | 1 | 2026 | 27 | 0.060 |
Why?
|
| Pediatrics | 1 | 2015 | 1205 | 0.060 |
Why?
|
| Community-Based Participatory Research | 1 | 2026 | 60 | 0.060 |
Why?
|
| Protease Inhibitors | 1 | 2006 | 92 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2006 | 138 | 0.060 |
Why?
|
| Program Development | 1 | 2026 | 181 | 0.060 |
Why?
|
| Risk | 2 | 2017 | 736 | 0.060 |
Why?
|
| Focus Groups | 1 | 2026 | 216 | 0.060 |
Why?
|
| Probability | 1 | 2025 | 307 | 0.060 |
Why?
|
| Cryptosporidium | 1 | 2004 | 27 | 0.060 |
Why?
|
| Family Health | 2 | 2005 | 248 | 0.050 |
Why?
|
| Comorbidity | 2 | 2019 | 1562 | 0.050 |
Why?
|
| Mice, Inbred NOD | 3 | 2016 | 290 | 0.050 |
Why?
|
| Pedigree | 2 | 2004 | 1656 | 0.050 |
Why?
|
| Neoplasms | 2 | 2013 | 2856 | 0.050 |
Why?
|
| Europe | 2 | 2014 | 362 | 0.050 |
Why?
|
| Liraglutide | 1 | 2022 | 13 | 0.050 |
Why?
|
| CTLA-4 Antigen | 2 | 2017 | 62 | 0.050 |
Why?
|
| Drug Monitoring | 2 | 2016 | 274 | 0.050 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2024 | 440 | 0.050 |
Why?
|
| Protein Tyrosine Phosphatases | 2 | 2001 | 76 | 0.050 |
Why?
|
| Mesonephroma | 1 | 2001 | 1 | 0.040 |
Why?
|
| Papilloma | 1 | 2001 | 22 | 0.040 |
Why?
|
| Vaginal Neoplasms | 1 | 2001 | 17 | 0.040 |
Why?
|
| Self Tolerance | 1 | 2001 | 4 | 0.040 |
Why?
|
| Incidence | 2 | 2013 | 3261 | 0.040 |
Why?
|
| Thymus Gland | 1 | 2001 | 100 | 0.040 |
Why?
|
| United Kingdom | 1 | 2001 | 235 | 0.040 |
Why?
|
| Microsatellite Repeats | 1 | 2001 | 229 | 0.040 |
Why?
|
| Body Composition | 2 | 2013 | 538 | 0.040 |
Why?
|
| Kidney | 1 | 2006 | 1283 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2024 | 1206 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2001 | 900 | 0.040 |
Why?
|
| Colectomy | 1 | 2019 | 92 | 0.040 |
Why?
|
| Parents | 1 | 2026 | 1077 | 0.040 |
Why?
|
| Epidemiologic Methods | 1 | 2018 | 94 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2019 | 384 | 0.040 |
Why?
|
| ROC Curve | 1 | 2020 | 587 | 0.030 |
Why?
|
| Artificial Limbs | 1 | 1997 | 7 | 0.030 |
Why?
|
| Educational Measurement | 1 | 2020 | 296 | 0.030 |
Why?
|
| Pinealoma | 1 | 1997 | 19 | 0.030 |
Why?
|
| Pineal Gland | 1 | 1997 | 21 | 0.030 |
Why?
|
| Models, Genetic | 1 | 2001 | 742 | 0.030 |
Why?
|
| Germinoma | 1 | 1997 | 30 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2019 | 6695 | 0.030 |
Why?
|
| Receptors, CCR7 | 1 | 2017 | 21 | 0.030 |
Why?
|
| Anthropometry | 1 | 2018 | 190 | 0.030 |
Why?
|
| Fat Emulsions, Intravenous | 1 | 1998 | 79 | 0.030 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 1997 | 61 | 0.030 |
Why?
|
| Patient Compliance | 1 | 2020 | 464 | 0.030 |
Why?
|
| Costs and Cost Analysis | 1 | 1997 | 155 | 0.030 |
Why?
|
| Neoadjuvant Therapy | 1 | 2019 | 385 | 0.030 |
Why?
|
| Learning | 1 | 2020 | 358 | 0.030 |
Why?
|
| Pituitary Neoplasms | 1 | 1997 | 77 | 0.030 |
Why?
|
| Medical Records | 1 | 1997 | 180 | 0.030 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2016 | 32 | 0.030 |
Why?
|
| Immunoglobulin G | 1 | 1999 | 773 | 0.030 |
Why?
|
| Parenteral Nutrition | 1 | 1998 | 214 | 0.030 |
Why?
|
| Cell Separation | 1 | 2016 | 219 | 0.030 |
Why?
|
| Injections, Subcutaneous | 1 | 2016 | 129 | 0.030 |
Why?
|
| Ambulatory Care Facilities | 1 | 2017 | 235 | 0.030 |
Why?
|
| Case-Control Studies | 2 | 2017 | 3325 | 0.030 |
Why?
|
| Cell Line | 1 | 2000 | 2565 | 0.030 |
Why?
|
| Transduction, Genetic | 1 | 2016 | 283 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2019 | 1291 | 0.030 |
Why?
|
| Mice | 4 | 2017 | 17686 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2019 | 1400 | 0.030 |
Why?
|
| Reoperation | 1 | 2018 | 821 | 0.030 |
Why?
|
| DNA | 1 | 2000 | 1421 | 0.030 |
Why?
|
| Curriculum | 1 | 2020 | 766 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2018 | 1147 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2016 | 318 | 0.030 |
Why?
|
| Drug Delivery Systems | 1 | 2016 | 204 | 0.030 |
Why?
|
| Transfection | 1 | 2016 | 948 | 0.030 |
Why?
|
| RNA, Long Noncoding | 1 | 2017 | 228 | 0.030 |
Why?
|
| Survival Rate | 1 | 1999 | 2111 | 0.030 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2017 | 578 | 0.030 |
Why?
|
| Multifactorial Inheritance | 1 | 2015 | 158 | 0.030 |
Why?
|
| Palliative Care | 1 | 2018 | 441 | 0.030 |
Why?
|
| Membrane Proteins | 2 | 2001 | 1569 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2016 | 770 | 0.030 |
Why?
|
| Trans-Activators | 1 | 2017 | 676 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 1999 | 2075 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2016 | 1232 | 0.030 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2017 | 583 | 0.030 |
Why?
|
| Infusion Pumps, Implantable | 1 | 2013 | 36 | 0.030 |
Why?
|
| Diet | 1 | 2000 | 1102 | 0.020 |
Why?
|
| Repressor Proteins | 1 | 2017 | 763 | 0.020 |
Why?
|
| Medically Uninsured | 1 | 2013 | 76 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2019 | 1273 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2015 | 479 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2016 | 1597 | 0.020 |
Why?
|
| Proteins | 1 | 2017 | 1019 | 0.020 |
Why?
|
| Length of Stay | 1 | 1997 | 1378 | 0.020 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2018 | 630 | 0.020 |
Why?
|
| Cause of Death | 1 | 2013 | 487 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2016 | 2311 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 1998 | 1309 | 0.020 |
Why?
|
| Algorithms | 1 | 2017 | 1635 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2013 | 1054 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2012 | 473 | 0.020 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 2 | 2001 | 7 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2017 | 1891 | 0.020 |
Why?
|
| Brain Neoplasms | 1 | 1997 | 1235 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2016 | 2995 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2017 | 2344 | 0.020 |
Why?
|
| Receptors, Interleukin-4 | 1 | 2005 | 11 | 0.010 |
Why?
|
| Antigens, Differentiation | 1 | 2005 | 63 | 0.010 |
Why?
|
| Israel | 1 | 2005 | 48 | 0.010 |
Why?
|
| Arabs | 1 | 2005 | 29 | 0.010 |
Why?
|
| Jews | 1 | 2005 | 33 | 0.010 |
Why?
|
| Interleukin-13 | 1 | 2005 | 94 | 0.010 |
Why?
|
| Atlantic Ocean | 1 | 2004 | 2 | 0.010 |
Why?
|
| Oocysts | 1 | 2004 | 3 | 0.010 |
Why?
|
| Histological Techniques | 1 | 2004 | 19 | 0.010 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2004 | 130 | 0.010 |
Why?
|
| Glutens | 1 | 2004 | 11 | 0.010 |
Why?
|
| Transglutaminases | 1 | 2004 | 27 | 0.010 |
Why?
|
| Species Specificity | 1 | 2004 | 516 | 0.010 |
Why?
|
| Antigens, CD | 1 | 2005 | 415 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2004 | 951 | 0.010 |
Why?
|
| Virus Diseases | 1 | 2005 | 271 | 0.010 |
Why?
|
| Denmark | 1 | 2001 | 29 | 0.010 |
Why?
|
| Clonal Deletion | 1 | 2001 | 3 | 0.010 |
Why?
|
| Proinsulin | 1 | 2001 | 13 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 2001 | 237 | 0.010 |
Why?
|
| Epithelium | 1 | 2001 | 340 | 0.010 |
Why?
|
| Intestinal Mucosa | 1 | 2004 | 754 | 0.010 |
Why?
|
| Vagina | 1 | 2001 | 203 | 0.010 |
Why?
|
| Lymphocytes | 1 | 2001 | 355 | 0.010 |
Why?
|
| Environment | 1 | 2000 | 150 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 2001 | 374 | 0.010 |
Why?
|
| Gene Expression | 1 | 2001 | 1485 | 0.010 |
Why?
|
| Triglycerides | 1 | 1998 | 596 | 0.010 |
Why?
|
| Apoptosis | 1 | 2001 | 1824 | 0.010 |
Why?
|
| Biomarkers, Tumor | 1 | 2001 | 1561 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 1997 | 3715 | 0.000 |
Why?
|